Predictive Oncology ends merger talks with Renovaro; no binding agreement signed

Axe Compute Inc.

POAI decided to discontinue discussions with RENB regarding the proposed merger.
POAI states it never entered into a merger agreement; RENB's April 4 press release claims were misrepresentations.
The letter of intent with RENB expired on March 31, 2025; POAI has no further obligations.
POAI reaffirms commitment to its AI-driven drug discovery and drug development business.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.